\
&
Contact us
\
&
Contact us
Published on | 5 years ago
ProgrammesERA-MIN 3 supports ambitious, transnational research and development projects within the following topics:
The 2021 call of ERA-MINUS 3 is now open with the deadline for the pre-proposals 1 April 2021.
The partners of the international project proposals receive support from their own country or region for their contribution to the project. Specific eligibility criteria and support modalities apply to each country or region. More information about the participating countries and regions can be found here.
Flanders Innovation & Entrepreneurship (VLAIO) uses the support programme for research and development projects to finance the Flemish share of ERA-MIN3 projects. More information can be found here.
The project leader of the international ERA-MIN3 project submits the project to ERA-MIN3 by 1 April 2021. As a Flemish participant. you must also submit a digital application for a research or development project with regard to the Flemish project part at VLAIO. Here you choose "international project" and "ERA-MIN" and download the corresponding templates. You submit this to VLAIO by the same date of 1 April 2021.
If you are a company based in Flanders and are considering submitting an application, whether or not in cooperation with a "Research partner", please contact VLAIO (elsie.declercq@vlaio.be) for further explanations and/or an exploratory conversation.
Looking forward to your request.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has amended the 2025-2027 Digital Europe main work programme. The amendment ("March 2026") can be found on the Commission website alongside the work programme. According to the amendment, the following call topics are part of the next round of calls: Digital solutions for regulatory compliance through data Apply AI: Pil... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
